Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01434095|
Recruitment Status : Completed
First Posted : September 14, 2011
Last Update Posted : September 15, 2011
A half-dose photodynamic therapy, a relative new treatment, has been widely performed to treat central serous chorioretinopathy.
The researchers aimed to investigate whether the therapy improved the patient's visual acuity as well as the retinal sensitivity. The researchers also investigate which clinical factors, if any, were associated with the results; visual acuity or retinal sensitivity after the treatment.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Central Serous Chorioretinopathy||Procedure: half-dose photodynamic therapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||October 2008|
|Actual Primary Completion Date :||July 2010|
|Actual Study Completion Date :||July 2010|
Active Comparator: half-dose PDT(photodynamic therapy)
The study include single arm; treated group, and no control group was included.
Procedure: half-dose photodynamic therapy
photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
- best corrected visual acuity [ Time Frame: one year ]
- retinal sensitivity [ Time Frame: one year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01434095
|Department of Ophthalmology, Surugadai Nihon University Hospital|
|Chiyoda-ku, Tokyo, Japan, 101-8309|
|Principal Investigator:||Kyoko Fujita, MD, PhD||Department of Ophthalmology, Surugadai Nihon University Hospital|